IGNYTA, INC. (NASDAQ:RXDX) Files An 8-K Regulation FD Disclosure

Item7.01

On November29, 2016, results from certain preclinical studies
were announced, including in four poster presentations, at the
2016 EORTC-NCI-AACR (ENA) Molecular Targets and Cancer
Therapeutics Symposium in Munich, Germany. The press release
dated November29, 2016, announcing the data from the poster
presentations is attached hereto as Exhibit 99.1.

The information contained in this Item7.01 and in Exhibit 99.1 of
this Current Report on Form 8-K shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.

(d)Exhibits.

1

About IGNYTA, INC. (NASDAQ:RXDX)

Ignyta, Inc. is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Its Dx focuses on pairing the product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients likely to benefit from the therapies. Its entrectinib is an orally bioavailable, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (Trk) family tyrosine kinase receptors (TrkA, TrkB and TrkC), ROS1 and anaplastic lymphoma kinase (ALK) proteins for the treatment of solid tumors. Its entrectinib is in Phase II/III of clinical development. Its taladegib is a small molecule and hedgehog or smoothened antagonist.

IGNYTA, INC. (NASDAQ:RXDX) Recent Trading Information

IGNYTA, INC. (NASDAQ:RXDX) closed its last trading session down -0.15 at 6.60 with shares trading hands.